NAFTA 2.0: Obstacles to More Affordable Medicines @accessiblemeds
NAFTA 2.0: Obstacles to More Affordable Medicines  @accessiblemeds
Uploaded April 2019 | Updated November 2026, 3 hours ago
Patients in the U.S. are already confronted by the world’s longest climb to affordable biosimilar medicines. NAFTA 2.0 (USMCA) will increase obstacles for life-saving medicines, keeping prices high and out of reach for patients. Learn more at: bit.ly/NAFTA-Obstacles-blog
NAFTA 2.0: Obstacles to More Affordable MedicinesAAM All Access - Vinita GuptaAccess! 2018 - Who You Need to KnowEileen is Singing, Dancing and Taking Care of Herself with BiosimilarsAAM Access 2018 Chip Davis State of AAM AddressAAM All Access - Thomas TighePeople are talking about GRx+Biosims – don’t miss out!Chip Davis on Panel: Opioid Epidemic: Youth Awareness & PreventionAAM Member Sandoz: Keren HaruviHelens Story — She Knows She Can Rely on BiosimilarsGPhA President & CEO Chip Davis 2016 Annual Meeting Keynote AddressAAM Interim CEO Jeff Francer: New Opportunities at the GRx+Biosims 2020 Virtual Conference
Association for Accessible Medicines |

NAFTA 2.0: Obstacles to More Affordable Medicines

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER